DDInter576 DDInter1578
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola.[A191379, A222393] Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated _in vitro_ activity against the _Arenaviridae_, _Flaviviridae_, _Filoviridae_, _Paramyxoviridae_, _Pneumoviridae_, and _Coronaviridae_ viral families. Remdesivir activity against the _Coronaviridae_ family was first demonstrated in 2017, leading to considerable interest in remdesivir as a possible treatment for COVID-19.[A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.[L12174, L12177] After initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020, remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22, 2020. Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc. Remdesivir was also approved by the European Commission on July 3, 2020. Remdesivir in combination with [baricitinib] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020.
Disulfiram {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Disulfiram {u} (Compound) upregulates {v} (Gene) GPC1
GPC1 {u} (Gene) is upregulated by {v} (Compound) Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Disulfiram {u} (Compound) upregulates {v} (Gene) RGS2
RGS2 {u} (Gene) is downregulated by {v} (Compound) Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Disulfiram {u} (Compound) causes {v} (Side Effect) Hepatic failure
Hepatic failure {u} (Side Effect) is caused by {v} (Compound) Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Disulfiram {u} (Compound) downregulates {v} (Gene) ARHGAP1
ARHGAP1 {u} (Gene) is upregulated by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Disulfiram {u} (Compound) downregulates {v} (Gene) ARHGAP1
ARHGAP1 {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Disulfiram {u} (Compound) downregulates {v} (Gene) ERBB3
ERBB3 {u} (Gene) is bound by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Disulfiram {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Disulfiram {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Hydroxychloroquine
Hydroxychloroquine {u} may lead to a major life threatening interaction when taken with {v} Remdesivir
Disulfiram {u} (Compound) treats {v} (Disease) alcohol dependence
alcohol dependence {u} (Disease) is treated by {v} (Compound) Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Disulfiram (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Pioglitazone (Compound) and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Disulfiram (Compound) upregulates GPC1 (Gene) and GPC1 (Gene) is upregulated by Pioglitazone (Compound) and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Disulfiram (Compound) upregulates RGS2 (Gene) and RGS2 (Gene) is downregulated by Pioglitazone (Compound) and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Disulfiram (Compound) causes Hepatic failure (Side Effect) and Hepatic failure (Side Effect) is caused by Pioglitazone (Compound) and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Disulfiram (Compound) downregulates ARHGAP1 (Gene) and ARHGAP1 (Gene) is upregulated by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Disulfiram (Compound) downregulates ARHGAP1 (Gene) and ARHGAP1 (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Disulfiram (Compound) downregulates ERBB3 (Gene) and ERBB3 (Gene) is bound by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Disulfiram (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Epirubicin (Compound) and TOP2A (Gene) is downregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Disulfiram (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Hydroxychloroquine (Compound) and Hydroxychloroquine may lead to a major life threatening interaction when taken with Remdesivir
Disulfiram (Compound) treats alcohol dependence (Disease) and alcohol dependence (Disease) is treated by Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir